Cathflo Activase Pediatric Study
Information source: Genentech, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dysfunctional Central Venous Access Devices (CVADS)
Intervention: Cathflo Activase (Alteplase) (Drug)
Phase: Phase 4
Sponsored by: Genentech, Inc.
Official(s) and/or principal investigator(s):
Martha Blaney, PharmD, Study Director, Affiliation: Genentech, Inc.
This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at
~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional
CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted
ports) were to be treated with up to two serially instilled doses of Cathflo Activase.
Official title: Cathflo Activase (Alteplase) Pediatric Study (CAPS)
Study design: Primary Purpose: Treatment
Primary outcome: To evaluate the safety, as measured by the incidence of intracranial hemorrhage during the treatment with Cathflo Activase, in restoring function to dysfunctional CVADs in pediatric populations.
Secondary outcome: To estimate the rate of restoration of function to dysfunctional CVADs following administration of up to two instillations of Cathflo Activase.
Minimum age: N/A.
Maximum age: 17 Years.
Subjects had to meet the following inclusion criteria to be eligible for study entry:
- Less than 17 years of age
- Clinically stable
- Occlusion of CVAD (including catheters with valves, multiple lumens, umbilical
catheters, and implanted ports)
- For subjects who weighed >= 10 kg, inability to withdraw 3 mL of blood from the CVAD
- For subjects who weighed < 10 kg, inability to withdraw 1 mL of blood from the CVAD
- Ability to infuse fluids at the volume necessary to instill Cathflo Activase into the
- Written informed consent and assent (if appropriate) provided by parent or legal
guardian and compliance with study assessments for the full duration of the study
- Ability to withdraw blood following subject repositioning
- CVAD insertion < 48 hours prior to enrollment
- Selected study catheter implanted specifically for hemodialysis
- Evidence of mechanical, non-thrombotic occlusion of the CVAD (e. g., kink in the CVAD
or suture constricting the catheter)
- Previous enrollment in this study
- Use of fibrinolytic agent (e. g., alteplase, reteplase, tenecteplase, urokinase,
streptokinase) within 24 hours of enrollment
- At high risk for bleeding events, embolic complications (i. e., recent pulmonary
embolism, deep vein thrombosis, endarterectomy, clinically significant right-to-left
shunt) in the opinion of the investigator, or with known condition for which
bleeding constituted a significant hazard
- Known hypersensitivity to alteplase or any component of the formulation
Locations and Contacts
Starting date: April 2002
Last updated: April 8, 2014